ClinicalTrials.gg
CompletedNCT03981549TRUSTUpdated Dec 2, 2024Results posted

Treatment of Central Retinal Vein Occlusion Using Stem Cells Study

A Phase 1/2 interventional study of Autologous Bone Marrow CD34+ Stem Cells and Sham Therapy in Central Retinal Vein Occlusion, sponsored by The Emmes Company, LLC. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-02.

Sponsored by The Emmes Company, LLC · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 106 studies in Retinal Vein Occlusion with a site in United States — 6 open to participants now, 10 under way, 1 of them phase 3. Retinal Vein Occlusion · United States.

Enrollment
69th of 90
16 · median 40
Started
2019
with 7 others
Phase 1/2
9 of 106
none open now
Registered
81st of 106
by date
Lead sponsor
3 of 106
The Emmes Company, LLC

Among the 106 studies in Retinal Vein Occlusion with a site in United States, this one is the 69th largest by enrollment of the 90 interventional ones that give a count, is one of 8 that started in 2019, is one of 9 in phase 1/2, and was the 81st registered.

Retinal Vein Occlusion

289 studies on the registry are indexed under Retinal Vein Occlusion; 32 are open to participants now.

Browse Retinal Vein Occlusion studies →

Open to participants now

6 of the 106 studies in Retinal Vein Occlusion with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 18 Retinal Vein Occlusion studies recruiting now, 13 (72%) set no upper age limit and none (0%) stop at 75 or younger; 1 takes children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 106 studies in Retinal Vein Occlusion with a site in United States, or all of them as a file.
02

Study summary

This study evaluates whether intravitreal autologous CD34+ stem cell therapy is safe, feasible and potentially beneficial in eyes with vision loss from central retinal vein occlusion (CRVO). Half of the participants will receive immediate cellular therapy followed by sham therapy 6 months later, while the other half will receive immediate sham therapy followed by cellular therapy 6 months later. Participants will be followed for a total of 1 year.

Read the detailed description

The goal of this phase I/II prospective, randomized, sham-controlled, double-masked clinical trial is to determine whether intravitreal autologous CD34+ stem cell therapy is safe, feasible and potentially beneficial in eyes with vision loss from central retinal vein occlusion (CRVO). Retinal Vein Occlusion (RVO) is a leading retinal vascular cause of vision loss in the elderly. CD34+ stem cells in human bone marrow are mobilized into the circulation in response to tissue ischemia for tissue revascularization and repair. Since local delivery of CD34+ stem cells benefits ischemic tissue, intravitreal delivery of CD34+ stem cells may benefit vision and retinal ischemia in eyes with RVO. A pilot clinical trial has shown no major safety or feasibility concerns using intravitreal autologous CD34+ bone marrow stem cells. In this proposed expanded phase I/II study, 20 participants (20 eyes) with persistent vision loss from CRVO will be enrolled and followed for 1 year.

Participants will be randomized 1:1 to immediate cell therapy/deferred sham therapy or immediate sham therapy/deferred cell therapy. At month 6, the cell treated eye will receive sham treatment and the sham treated eye will get cell therapy. The cellular therapy involves bone marrow aspiration, isolation of CD34+ cells from the aspirate under Good Manufacturing Practice (GMP) conditions, and intravitreal injection of isolated CD34+ cells. The sham therapy involves a sham bone marrow aspiration with penetration of the skin but no penetration of the bone and a sham intravitreal injection without penetrating the eye. The participant, examining ophthalmologist, visual acuity examiner, photographers and OCT, perimetry, and electroretinography (ERG) technicians will remain masked to study treatment assignment for study duration. A comprehensive eye examination with ETDRS best-corrected visual acuity, optical coherence tomography (OCT) and OCT angiography (OCTA), autofluorescence, fundus photography, fluorescein angiography, microperimetry, and electroretinography will be performed at baseline and serially. A subset of participants with good fixation on microperimetry and clear media on exam and commercial-grade OCTA and who give consent will have ultra-high resolution cellular retinal imaging using research-grade OCT and OCTA and adaptive optics-OCT at baseline. Participants with high quality images will have repeat imaging at 1 month after stem cell treatment, with at least 2 of the participants randomized to the deferred cellular therapy arm also having imaging 1 month after sham therapy. Post-release flow cytometry characterization will be performed to determine the composition of the CD34+ enriched final product in terms of hematopoietic versus angiogenic stem cells based on cell surface markers (i.e., CD133(+)/CD45(+)/CD34(+) vs CD31(+)/VEGFR-2(+)/CD45(-)/CD34(+)). The long-term objective is to determine whether intravitreal autologous CD34+ cell therapy can minimize, or reverse vision loss associated with retinal ischemia without compromising safety.

03

Conditions studied

  • Central Retinal Vein Occlusion

Keywords

  • Central Retinal Vein Occlusion
  • Retinal Vein Occlusion
  • Retinal Diseases
  • Eye Diseases
  • CD34+ Stem Cell Therapy
  • Autologous Bone Marrow Stem Cells
  • Stem Cells
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Study Eye Inclusion/Exclusion Criteria:

Inclusion criteria

Inclusion criteria for the study eye:

  • Clinical diagnosis of central retinal vein occlusion (CRVO) confirmed by review of medical records and screening assessment.
  • Best Corrected Visual Acuity (BCVA) obtained during the screening period is in the range of 20/40+ to 20/400- (ETDRS letter score in the range of 18 to 73, inclusive).
  • Duration of vision loss from CRVO >= 6 months to \<=42 months.

Exclusion criteria

Exclusion criteria for the study eye:

  • Previous eye treatment with intravitreal or periocular , laser or intraocular surgery within 6 months prior to enrollment (i.e., date ICF signed) or treatment expected to be given during the study period.
  • For eyes requiring treatment to prevent recurrent macular edema, on-going intravitreal anti-VEGF treatment is expected to be given at an interval \< every 8 weeks during the study period or anti-VEGF therapy was started less than 24 weeks prior to .
  • History of concurrent ocular herpes infection.
  • Active non-herpetic eye infection diagnosed within 8 weeks from enrollment (i.e., date Informed Consent Form (ICF) signed).
  • Glaucoma requiring treatment with more than 2 medications, laser or intraocular surgery.
  • Active uveitis or history of recurrent uveitis or uveitis involving the posterior segment.
  • Presence of cataract that is impairing vision.
  • Presence of lens or lens implant subluxation.
  • History of ocular trauma that is currently impairing vision.
  • Any concurrent optic nerve or retinal disease that is visually significant or likely to progress to visual significance during the 1-year study follow-up. The excluded eyes include eyes with AREDS category 2 to 3 age-related macular degeneration (AMD) with foveal involvement of drusen or RPE changes, and any AREDS category 4 AMD eyes. For eyes with ERM, the excluded eyes include eyes with OCT evidence of foveal deformation. For optic nerve disease, eyes with any associated visual field deficit or history of associated CNVM are excluded. For glaucoma eyes, eyes requiring glaucoma laser trabeculectomy or glaucoma surgery to maintain IOP are excluded.
  • Active retinal or iris neovascularization.
  • Macular edema requiring on-going therapy or where treatment is expected during the study period, with the exception of anti-VEGF treatment given at an interval of 8 weeks or greater.
  • Significant media opacity precluding view of the fundus for examination, photography or optical coherence tomography (OCT) including cataract and vitreous haze.
  • High myopia (>= 9 diopters)
  • Amblyopia
  • Other cause contributing to vision loss at screening.
  • History of any of the following procedures: corneal transplant, glaucoma surgery, or intraocular silicone oil.

Participant-level Inclusion/Exclusion Criteria:

Participant-level inclusion criteria:

  • Age >=18 years
  • Female participants of must not be pregnant or breastfeeding and have a negative urine pregnancy test within 14 days prior to sham injection and/or CD34+ cell injection.
  • Females of childbearing potential must have had a hysterectomy, be completely abstinent from intercourse or must agree to practice effective for the duration of the study. Acceptable methods of contraception include hormonal contraception, intrauterine device, barrier methods (diaphragm, condom) with spermicide, or surgical sterilization (tubal ligation).
  • Able and willing to sign informed consent.
  • Able to keep follow-up appointments for at least 12 months as determined by the investigator.

Participant-level exclusion criteria:

  • Concurrent treatment with an drug or device.
  • Concurrent use of systemic therapy or history of use within 3 months prior to enrollment (i.e., date ICF signed).
  • Concurrent use of anticoagulation therapy except for aspirin without an acceptable safe stopping plan for study treatments.
  • Known history of coagulopathy or other hematologic abnormality that may put participant at risk for bleeding or infection or raise concerns about quality or quantity of CD34+ cells isolated.
  • History of allergy to fluorescein dye.
  • Participant who has had a prior or concomitant with the exception of the following: 1) adequately treated basal or squamous cell carcinoma of the skin, or 2) any other malignancy from which the patient has remained disease free for more than five years.
  • Current active systemic infection as evidenced by fever greater than 100.4 or any evidence of systemic infection as determined by the study physician.
  • Any diagnosis of active infection or vaccination within 8 weeks of study treatment.
  • Diabetes mellitus with known systemic complications by self-report or physician-determined by medical history or examination.
  • History of prior radiotherapy to head/neck area.
  • Poorly controlled hypertension with systolic > 180 or diastolic > 95.
  • Serious medical or psychiatric condition that, in the opinion of the Investigator, would make study participation hazardous to the participant or compromise study findings or would prevent the participant from completing the study.
  • Any physical characteristic that precludes ability to perform study diagnostic testing.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
16 participants (actual)

Study arms

  • Active comparator
    Immediate Cellular Therapy / Deferred Sham Therapy

    At baseline: Bone marrow aspiration followed by intravitreal injection of CD34+ cells. At 6 months: Sham bone marrow aspiration and sham intravitreal injection.

    Biological: Autologous Bone Marrow CD34+ Stem Cells · Biological: Sham Therapy

  • Sham comparator
    Immediate Sham Therapy / Deferred Cellular Therapy

    At baseline: Sham bone marrow aspiration followed by sham intravitreal injection. At 6 months: Bone marrow aspiration followed by intravitreal injection of CD34+ cells.

    Biological: Autologous Bone Marrow CD34+ Stem Cells · Biological: Sham Therapy

Interventions

  • BiologicalAutologous Bone Marrow CD34+ Stem Cells

    Single intravitreal injection of autologous bone marrow CD34+ stem cells. The number of cells to be injected per eye will range from 800,000 to 10 million, depending on the yield of the bone marrow aspiration and the isolation procedure.

  • BiologicalSham Therapy

    Sham bone marrow aspiration procedure that penetrates the skin, but does not penetrate the bone followed by sham intravitreal injection without penetration of the eye

06

What researchers measure

Primary outcomes

  1. Incidence and Severity of Ocular and Systemic Adverse Events

    The primary safety outcome will be assessed at month 6. Adverse events (AE) that occur during the first 6 months of the trial will be broken down by whether the AE occurred following the sham or cellular treatment to assess differences in the adverse event experience between the cellular and sham therapies.

    Time frame: Months 0 to 6

  2. Feasibility of the Stem Cell Therapy

    Number of CD34+ cells isolated from the bone marrow aspirate and number of cells injected into the eye

    Time frame: Day 0 and Day 182

Secondary outcomes

  1. Change in Early Treatment Diabetic Retinopathy Study (ETDRS) Visual Acuity Letter Score

    Mean change from baseline of visual acuity letter score at Month 6. The measure is calculated by subtracting the baseline visual acuity letter score from the month 6 visual acuity letter score. The participant is refracted for best corrected vision, and then reads single letters from the ETDRS charts using a visual acuity light box at a 4 meter distance (or 1 meter for participants with sufficiently reduced vision) according to a specific algorithm. A letter score is provided that ranges from 0 (unable to read any letters) to 100. A visual acuity letter score of 85 corresponds to a visual acuity of 20/20 as a Snellen equivalent. Higher is better.

    Time frame: Months 0 to 6

  2. Change in % Reduced Sensitivity

    Mean change from baseline of % reduced sensitivity at Month 6 as measured by microperimetry (decrease is better)

    Time frame: Months 0 to 6

  3. Change in Average Threshold

    Mean change from baseline of average threshold (dB) at Month 6 as measured by microperimetry (increase is better)

    Time frame: Months 0 to 6

  4. Change in Percent Normal Amplitude for ERG+OP (Oscillatory Potential) A-wave Under Scotopic Conditions

    Mean change from baseline of percent of normal amplitude for ERG+OP a-wave under scotopic conditions at Month 6 as measured by Full-field ERG (increase is better)

    Time frame: Months 0 to 6

  5. Change in Percent Normal Amplitude for ERG+OP B-wave Under Scotopic Conditions

    Mean change from baseline of percent of normal amplitude for ERG+OP b-wave under scotopic conditions at Month 6 as measured by Full-field ERG (increase is better)

    Time frame: Months 0 to 6

  6. Change in Percent Normal Latency of ERG+OP A-wave Under Scotopic Conditions

    Mean change from baseline of percent normal latency of ERG+OP a-wave under scotopic conditions at Month 6 as measured by Full-field ERG (decrease is better)

    Time frame: Months 0 to 6

  7. Change in Percent Normal Latency of ERG+OP B-wave Under Scotopic Conditions

    Mean change from baseline of percent normal latency of ERG+OP b-wave under scotopic conditions at Month 6 as measured by Full-field ERG (decrease is better)

    Time frame: Months 0 to 6

  8. Change in Percent Normal Amplitude for A-wave Under Photopic Conditions

    Mean change from baseline of percent normal amplitude for a-wave under photopic conditions at Month 6 as measured by Full-field ERG (increase is better)

    Time frame: Months 0 to 6

  9. Change in Percent Normal Amplitude for B-wave Under Photopic Conditions

    Mean change from baseline of percent normal amplitude for b-wave under photopic conditions at Month 6 as measured by Full-field ERG (increase is better)

    Time frame: Months 0 to 6

  10. Change in Percent Normal Latency for A-wave Under Photopic Conditions

    Mean change from baseline of percent normal latency for a-wave under photopic conditions at Month 6 as measured by Full-field ERG (decrease is better)

    Time frame: Months 0 to 6

  11. Change in Percent Normal Latency for B-wave Under Photopic Conditions

    Mean change from baseline of percent normal latency for b-wave under photopic conditions at Month 6 as measured by Full-field ERG (decrease is better)

    Time frame: Months 0 to 6

  12. Change in Percent Normal Flicker Amplitude

    Mean change from baseline in percent normal flicker amplitude at Month 6 as measured by Full-field ERG (increase is better)

    Time frame: Months 0 to 6

  13. Change in Flicker Latency Trough

    Mean change from baseline of latency trough at Month 6 as measured by Full-field ERG (decrease is better)

    Time frame: Months 0 to 6

  14. Change in Percent Normal Amplitude for A-wave Under Scotopic Conditions

    Mean change from baseline of percent normal amplitude for a-wave under scotopic conditions at Month 6 as measured by Full-field ERG (increase is better)

    Time frame: Months 0 to 6

  15. Change in Percent Normal Latency of A-wave Under Scotopic Conditions

    Mean change from baseline of percent normal latency of a-wave under scotopic conditions at Month 6 as measured by Full-field ERG (decrease is better)

    Time frame: Months 0 to 6

  16. Change in Percent Normal Amplitude for B-wave Under Scotopic Conditions

    Mean change from baseline of percent normal amplitude for b-wave under scotopic conditions at Month 6 as measured by Full-field ERG (increase is better)

    Time frame: Months 0 to 6

  17. Change in Percent Normal Latency for B-wave Under Scotopic Conditions

    Mean change from baseline of percent normal latency for b-wave under scotopic conditions at Month 6 as measured by Full-field ERG (decrease is better)

    Time frame: Months 0 to 6

  18. Foveal Avascular Zone Integrity

    Number of study eyes in each of the following categories as it relates to the integrity of the foveal avascular zone: Intact, Questionable, Disrupted (\<900 microns), Disrupted (900-1800 microns), Disrupted (\>1800 microns), and Cannot grade. Measured at Month 6 by fluorescein angiogram

    Time frame: 6 months

  19. Change in Area of Non-perfusion Within ETDRS Grid

    Mean change from baseline of area of non-perfusion within ETDRS grid at Month 6 as measured by fluorescein angiogram (decrease is better)

    Time frame: Months 0 to 6

  20. Change in Area of Non-perfusion Within Networc Grid

    Mean change from baseline of area of non-perfusion within Networc grid at Month 6 as measured by fluorescein angiogram (decrease is better)

    Time frame: Months 0 to 6

07

Results

Posted Dec 2, 2024

Participant flow

Participant flow — Overall Study
MilestoneImmediate Cellular Therapy / Deferred Sham TherapyImmediate Sham Therapy / Deferred Cellular Therapy
Started79
Completed79
Not completed00

Outcome measures

PrimaryIncidence and Severity of Ocular and Systemic Adverse Events

The primary safety outcome will be assessed at month 6. Adverse events (AE) that occur during the first 6 months of the trial will be broken down by whether the AE occurred following the sham or cellular treatment to assess differences in the adverse event experience between the cellular and sham therapies.

Time frame:
Months 0 to 6
Reported as:
Number · participants
Incidence and Severity of Ocular and Systemic Adverse Events
participantsImmediate Cellular Therapy / Deferred Sham TherapyImmediate Sham Therapy / Deferred Cellular Therapy
Altered visual depth perception in study eye10
Chalazion in study eye01
Cystoid macular oedema in study eye01
Dermatochalasis in study eye01
Dry eye in study eye24
Eye irritation in study eye54
Eye pain in study eye42
Eye puritis in study eye11
Foreign body sensation in study eye23
Meibomian gland dysfuntion in study eye11
Ocular hyperaemia in study eye33
Periorbital irritation in study eye01
Photopsia in study eye01
Presbyopia in study eye10
Swelling of eyelid in study eye10
Vision blurred in study eye11
Visual acuity reduced in study eye01
Visual impairment in study eye20
Vitreous degeneration in study eye10
Vitreous detachment in study eye10
Vitreous floaters in study eye60
Cystoid macular oedema in fellow eye01
Visual impairment in fellow eye11
Vitreous floaters in fellow eye11
Abdominal pain upper01
Acarodermatitis01
Anaemia01
Appendicitis01
Arthralgia10
Arthropod bite10
Back pain11
Basal cell carcinoma10
Cholelithiasis10
Chronic kidney disease10
Dizziness10
Epicondylitis01
Fall03
Foot deformity01
Heat exhaustion01
Hypertension20
Immunisation reaction13
Migraine01
Neuralgia10
Osteoarthritis10
Pain in extremity10
Palpitations10
Procedural pain01
Rash01
Rectal haemorrhage01
Rib fracture01
Sciatica01
Soft tissue mass10
Squamous cell carcinoma of skin10
Upper respiratory tract infection11
White blood cell count decreased10
PrimaryFeasibility of the Stem Cell Therapy

Number of CD34+ cells isolated from the bone marrow aspirate and number of cells injected into the eye

Time frame:
Day 0 and Day 182
Reported as:
Mean · Number of cells in millions
Feasibility of the Stem Cell Therapy
Number of cells in millionsImmediate Cellular Therapy / Deferred Sham TherapyImmediate Sham Therapy / Deferred Cellular Therapy
Number of CD34+ cells isolated from the bone marrow aspirate (pre-release)5.4 ± 2.205.9 ± 4.65
Number of CD34+ cells injected into the eye (pre-release)3.8 ± 1.694.6 ± 4.14
SecondaryChange in Early Treatment Diabetic Retinopathy Study (ETDRS) Visual Acuity Letter Score

Mean change from baseline of visual acuity letter score at Month 6. The measure is calculated by subtracting the baseline visual acuity letter score from the month 6 visual acuity letter score. The participant is refracted for best corrected vision, and then reads single letters from the ETDRS charts using a visual acuity light box at a 4 meter distance (or 1 meter for participants with sufficiently reduced vision) according to a specific algorithm. A letter score is provided that ranges from 0 (unable to read any letters) to 100. A visual acuity letter score of 85 corresponds to a visual acuity of 20/20 as a Snellen equivalent. Higher is better.

Time frame:
Months 0 to 6
Reported as:
Mean · Letters read
Change in Early Treatment Diabetic Retinopathy Study (ETDRS) Visual Acuity Letter Score
Letters readImmediate Cellular Therapy / Deferred Sham TherapyImmediate Sham Therapy / Deferred Cellular Therapy
Change in Early Treatment Diabetic Retinopathy Study (ETDRS) Visual Acuity Letter Score1.7 ± 3.822.1 ± 10.98
SecondaryChange in % Reduced Sensitivity

Mean change from baseline of % reduced sensitivity at Month 6 as measured by microperimetry (decrease is better)

Time frame:
Months 0 to 6
Reported as:
Mean · percent reduced
Change in % Reduced Sensitivity
percent reducedImmediate Cellular Therapy / Deferred Sham TherapyImmediate Sham Therapy / Deferred Cellular Therapy
Change in % Reduced Sensitivity0.8 ± 14.00-11.4 ± 16.81
SecondaryChange in Average Threshold

Mean change from baseline of average threshold (dB) at Month 6 as measured by microperimetry (increase is better)

Time frame:
Months 0 to 6
Reported as:
Mean · dB
Change in Average Threshold
dBImmediate Cellular Therapy / Deferred Sham TherapyImmediate Sham Therapy / Deferred Cellular Therapy
Change in Average Threshold-1.2 ± 2.990.0 ± 3.83
SecondaryChange in Percent Normal Amplitude for ERG+OP (Oscillatory Potential) A-wave Under Scotopic Conditions

Mean change from baseline of percent of normal amplitude for ERG+OP a-wave under scotopic conditions at Month 6 as measured by Full-field ERG (increase is better)

Time frame:
Months 0 to 6
Reported as:
Mean · percent normal amplitude
Change in Percent Normal Amplitude for ERG+OP (Oscillatory Potential) A-wave Under Scotopic Conditions
percent normal amplitudeImmediate Cellular Therapy / Deferred Sham TherapyImmediate Sham Therapy / Deferred Cellular Therapy
Change in Percent Normal Amplitude for ERG+OP (Oscillatory Potential) A-wave Under Scotopic Conditions-7.7 ± 36.8418.6 ± 18.15
SecondaryChange in Percent Normal Amplitude for ERG+OP B-wave Under Scotopic Conditions

Mean change from baseline of percent of normal amplitude for ERG+OP b-wave under scotopic conditions at Month 6 as measured by Full-field ERG (increase is better)

Time frame:
Months 0 to 6
Reported as:
Mean · percent normal amplitude
Change in Percent Normal Amplitude for ERG+OP B-wave Under Scotopic Conditions
percent normal amplitudeImmediate Cellular Therapy / Deferred Sham TherapyImmediate Sham Therapy / Deferred Cellular Therapy
Change in Percent Normal Amplitude for ERG+OP B-wave Under Scotopic Conditions-8.4 ± 48.9411.6 ± 22.50
SecondaryChange in Percent Normal Latency of ERG+OP A-wave Under Scotopic Conditions

Mean change from baseline of percent normal latency of ERG+OP a-wave under scotopic conditions at Month 6 as measured by Full-field ERG (decrease is better)

Time frame:
Months 0 to 6
Reported as:
Mean · percent normal latency
Change in Percent Normal Latency of ERG+OP A-wave Under Scotopic Conditions
percent normal latencyImmediate Cellular Therapy / Deferred Sham TherapyImmediate Sham Therapy / Deferred Cellular Therapy
Change in Percent Normal Latency of ERG+OP A-wave Under Scotopic Conditions1.3 ± 21.59-9.0 ± 8.33
SecondaryChange in Percent Normal Latency of ERG+OP B-wave Under Scotopic Conditions

Mean change from baseline of percent normal latency of ERG+OP b-wave under scotopic conditions at Month 6 as measured by Full-field ERG (decrease is better)

Time frame:
Months 0 to 6
Reported as:
Mean · percent normal latency
Change in Percent Normal Latency of ERG+OP B-wave Under Scotopic Conditions
percent normal latencyImmediate Cellular Therapy / Deferred Sham TherapyImmediate Sham Therapy / Deferred Cellular Therapy
Change in Percent Normal Latency of ERG+OP B-wave Under Scotopic Conditions12.7 ± 42.38-1.2 ± 24.95
SecondaryChange in Percent Normal Amplitude for A-wave Under Photopic Conditions

Mean change from baseline of percent normal amplitude for a-wave under photopic conditions at Month 6 as measured by Full-field ERG (increase is better)

Time frame:
Months 0 to 6
Reported as:
Mean · percent normal amplitude
Change in Percent Normal Amplitude for A-wave Under Photopic Conditions
percent normal amplitudeImmediate Cellular Therapy / Deferred Sham TherapyImmediate Sham Therapy / Deferred Cellular Therapy
Change in Percent Normal Amplitude for A-wave Under Photopic Conditions6.2 ± 35.8426.8 ± 79.01
SecondaryChange in Percent Normal Amplitude for B-wave Under Photopic Conditions

Mean change from baseline of percent normal amplitude for b-wave under photopic conditions at Month 6 as measured by Full-field ERG (increase is better)

Time frame:
Months 0 to 6
Reported as:
Mean · percent normal amplitude
Change in Percent Normal Amplitude for B-wave Under Photopic Conditions
percent normal amplitudeImmediate Cellular Therapy / Deferred Sham TherapyImmediate Sham Therapy / Deferred Cellular Therapy
Change in Percent Normal Amplitude for B-wave Under Photopic Conditions-2.5 ± 21.83-6.0 ± 22.83
SecondaryChange in Percent Normal Latency for A-wave Under Photopic Conditions

Mean change from baseline of percent normal latency for a-wave under photopic conditions at Month 6 as measured by Full-field ERG (decrease is better)

Time frame:
Months 0 to 6
Reported as:
Mean · percent normal latency
Change in Percent Normal Latency for A-wave Under Photopic Conditions
percent normal latencyImmediate Cellular Therapy / Deferred Sham TherapyImmediate Sham Therapy / Deferred Cellular Therapy
Change in Percent Normal Latency for A-wave Under Photopic Conditions-3.5 ± 20.19-0.0 ± 13.08
SecondaryChange in Percent Normal Latency for B-wave Under Photopic Conditions

Mean change from baseline of percent normal latency for b-wave under photopic conditions at Month 6 as measured by Full-field ERG (decrease is better)

Time frame:
Months 0 to 6
Reported as:
Mean · percent normal latency
Change in Percent Normal Latency for B-wave Under Photopic Conditions
percent normal latencyImmediate Cellular Therapy / Deferred Sham TherapyImmediate Sham Therapy / Deferred Cellular Therapy
Change in Percent Normal Latency for B-wave Under Photopic Conditions-0.1 ± 10.26-4.7 ± 7.59
SecondaryChange in Percent Normal Flicker Amplitude

Mean change from baseline in percent normal flicker amplitude at Month 6 as measured by Full-field ERG (increase is better)

Time frame:
Months 0 to 6
Reported as:
Mean · percent normal flicker amplitude
Change in Percent Normal Flicker Amplitude
percent normal flicker amplitudeImmediate Cellular Therapy / Deferred Sham TherapyImmediate Sham Therapy / Deferred Cellular Therapy
Change in Percent Normal Flicker Amplitude-10.8 ± 14.102.2 ± 15.08
SecondaryChange in Flicker Latency Trough

Mean change from baseline of latency trough at Month 6 as measured by Full-field ERG (decrease is better)

Time frame:
Months 0 to 6
Reported as:
Mean · percent latency trough
Change in Flicker Latency Trough
percent latency troughImmediate Cellular Therapy / Deferred Sham TherapyImmediate Sham Therapy / Deferred Cellular Therapy
Change in Flicker Latency Trough-4.2 ± 8.92-0.3 ± 8.12
SecondaryChange in Percent Normal Amplitude for A-wave Under Scotopic Conditions

Mean change from baseline of percent normal amplitude for a-wave under scotopic conditions at Month 6 as measured by Full-field ERG (increase is better)

Time frame:
Months 0 to 6
Reported as:
Mean · percent normal amplitude
Change in Percent Normal Amplitude for A-wave Under Scotopic Conditions
percent normal amplitudeImmediate Cellular Therapy / Deferred Sham TherapyImmediate Sham Therapy / Deferred Cellular Therapy
Change in Percent Normal Amplitude for A-wave Under Scotopic Conditions8.2 ± 42.653.8 ± 48.29
SecondaryChange in Percent Normal Latency of A-wave Under Scotopic Conditions

Mean change from baseline of percent normal latency of a-wave under scotopic conditions at Month 6 as measured by Full-field ERG (decrease is better)

Time frame:
Months 0 to 6
Reported as:
Mean · percent normal latency
Change in Percent Normal Latency of A-wave Under Scotopic Conditions
percent normal latencyImmediate Cellular Therapy / Deferred Sham TherapyImmediate Sham Therapy / Deferred Cellular Therapy
Change in Percent Normal Latency of A-wave Under Scotopic Conditions12.4 ± 56.19-14.7 ± 24.81
SecondaryChange in Percent Normal Amplitude for B-wave Under Scotopic Conditions

Mean change from baseline of percent normal amplitude for b-wave under scotopic conditions at Month 6 as measured by Full-field ERG (increase is better)

Time frame:
Months 0 to 6
Reported as:
Mean · percent normal amplitude
Change in Percent Normal Amplitude for B-wave Under Scotopic Conditions
percent normal amplitudeImmediate Cellular Therapy / Deferred Sham TherapyImmediate Sham Therapy / Deferred Cellular Therapy
Change in Percent Normal Amplitude for B-wave Under Scotopic Conditions-1.7 ± 35.7519.2 ± 34.67
SecondaryChange in Percent Normal Latency for B-wave Under Scotopic Conditions

Mean change from baseline of percent normal latency for b-wave under scotopic conditions at Month 6 as measured by Full-field ERG (decrease is better)

Time frame:
Months 0 to 6
Reported as:
Mean · percent normal latency
Change in Percent Normal Latency for B-wave Under Scotopic Conditions
percent normal latencyImmediate Cellular Therapy / Deferred Sham TherapyImmediate Sham Therapy / Deferred Cellular Therapy
Change in Percent Normal Latency for B-wave Under Scotopic Conditions-4.9 ± 12.32-5.7 ± 14.47
SecondaryFoveal Avascular Zone Integrity

Number of study eyes in each of the following categories as it relates to the integrity of the foveal avascular zone: Intact, Questionable, Disrupted (\<900 microns), Disrupted (900-1800 microns), Disrupted (\>1800 microns), and Cannot grade. Measured at Month 6 by fluorescein angiogram

Time frame:
6 months
Reported as:
Count of participants · Participants
Foveal Avascular Zone Integrity
ParticipantsImmediate Cellular Therapy / Deferred Sham TherapyImmediate Sham Therapy / Deferred Cellular Therapy
Foveal Avascular Zone Integrity at Baseline — Intact01
Foveal Avascular Zone Integrity at Baseline — Questionable22
Foveal Avascular Zone Integrity at Baseline — Disrupted (<900 microns)12
Foveal Avascular Zone Integrity at Baseline — Disrupted (900-1800 microns)14
Foveal Avascular Zone Integrity at Baseline — Disrupted (>1800 microns)30
Foveal Avascular Zone Integrity at Baseline — Cannot grade00
Foveal Avascular Zone Integrity at Month 6 — Intact02
Foveal Avascular Zone Integrity at Month 6 — Questionable20
Foveal Avascular Zone Integrity at Month 6 — Disrupted (<900 microns)22
Foveal Avascular Zone Integrity at Month 6 — Disrupted (900-1800 microns)24
Foveal Avascular Zone Integrity at Month 6 — Disrupted (>1800 microns)10
Foveal Avascular Zone Integrity at Month 6 — Cannot grade01
SecondaryChange in Area of Non-perfusion Within ETDRS Grid

Mean change from baseline of area of non-perfusion within ETDRS grid at Month 6 as measured by fluorescein angiogram (decrease is better)

Time frame:
Months 0 to 6
Reported as:
Mean · mm^2
Change in Area of Non-perfusion Within ETDRS Grid
mm^2Immediate Cellular Therapy / Deferred Sham TherapyImmediate Sham Therapy / Deferred Cellular Therapy
Change in Area of Non-perfusion Within ETDRS Grid1.4 ± 2.54-3.3 ± 6.32
SecondaryChange in Area of Non-perfusion Within Networc Grid

Mean change from baseline of area of non-perfusion within Networc grid at Month 6 as measured by fluorescein angiogram (decrease is better)

Time frame:
Months 0 to 6
Reported as:
Mean · mm^2
Change in Area of Non-perfusion Within Networc Grid
mm^2Immediate Cellular Therapy / Deferred Sham TherapyImmediate Sham Therapy / Deferred Cellular Therapy
Change in Area of Non-perfusion Within Networc Grid0.2 ± 152.7028.0 ± 53.61

Adverse events

Collected over Baseline to Month 12. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Immediate Cellular Therapy / Deferred Sham Therapy: Months 0-60/7 (0%)0/7 (0%)7/7 (100%)
Immediate Sham Therapy / Deferred Cellular Therapy: Months 0-60/9 (0%)1/9 (11.1%)9/9 (100%)
Immediate Cellular Therapy / Deferred Sham Therapy: Months 6-120/7 (0%)1/7 (14.3%)7/7 (100%)
Immediate Sham Therapy / Deferred Cellular Therapy: Months 6-120/9 (0%)0/9 (0%)9/9 (100%)
Most frequent serious events
Most frequent serious events
EventImmediate Cellular Therapy / Deferred Sham Therapy: Months 0-6Immediate Sham Therapy / Deferred Cellular Therapy: Months 0-6Immediate Cellular Therapy / Deferred Sham Therapy: Months 6-12Immediate Sham Therapy / Deferred Cellular Therapy: Months 6-12
Vitreous haemorrhageEye disorders0/70/91/70/9
Iris NeovascularizationEye disorders0/70/91/70/9
AppendicitisInfections and infestations0/71/90/70/9
Most frequent other events
Showing 10 of 70
Most frequent other events
EventImmediate Cellular Therapy / Deferred Sham Therapy: Months 0-6Immediate Sham Therapy / Deferred Cellular Therapy: Months 0-6Immediate Cellular Therapy / Deferred Sham Therapy: Months 6-12Immediate Sham Therapy / Deferred Cellular Therapy: Months 6-12
Vitreous floatersEye disorders6/71/90/79/9
Eye irritationEye disorders5/74/93/74/9
Eye painEye disorders4/72/93/74/9
Foreign body sensation in eyesEye disorders2/73/94/74/9
Ocular hyperaemiaEye disorders3/73/94/75/9
Dry eyeEye disorders2/74/90/72/9
Visual impairmentEye disorders3/71/93/72/9
FallInjury, poisoning and procedural complications0/73/90/70/9
Immunisation reactionInjury, poisoning and procedural complications1/73/91/73/9
Vision blurredEye disorders1/71/92/71/9

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Immediate Cellular Therapy / Deferred Sham TherapyImmediate Sham Therapy / Deferred Cellular TherapyTotal
<=18 years000
Between 18 and 65 years257
>=65 years549
Age, Continuous
Age, Continuous(years)Immediate Cellular Therapy / Deferred Sham TherapyImmediate Sham Therapy / Deferred Cellular TherapyTotal
Mean67.9 ± 12.5962.7 ± 12.6264.9 ± 12.47
Sex: Female, Male
Sex: Female, Male(Participants)Immediate Cellular Therapy / Deferred Sham TherapyImmediate Sham Therapy / Deferred Cellular TherapyTotal
Female325
Male4711
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Immediate Cellular Therapy / Deferred Sham TherapyImmediate Sham Therapy / Deferred Cellular TherapyTotal
Hispanic or Latino011
Not Hispanic or Latino7815
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Immediate Cellular Therapy / Deferred Sham TherapyImmediate Sham Therapy / Deferred Cellular TherapyTotal
American Indian or Alaska Native000
Asian022
Native Hawaiian or Other Pacific Islander000
Black or African American000
White7714
More than one race000
Unknown or Not Reported000
08

Study locations

1 site
  • Department of Ophthalmology & Vision Science, University of California Davis Eye Center
    Sacramento, California 95817, United States
09

References and documents

Publications

  • Park SS, Bauer G, Abedi M, Pontow S, Panorgias A, Jonnal R, Zawadzki RJ, Werner JS, Nolta J. Intravitreal autologous bone marrow CD34+ cell therapy for ischemic and degenerative retinal disorders: preliminary phase 1 clinical trial findings. Invest Ophthalmol Vis Sci. 2014 Dec 9;56(1):81-9. doi: 10.1167/iovs.14-15415. PubMed 25491299 ↗
  • Park SS, Bauer G, Fury B, Abedi M, Perotti N, Colead-Bergum D, Nolta JA. Phase I Study of Intravitreal Injection of Autologous CD34+ Stem Cells from Bone Marrow in Eyes with Vision Loss from Retinitis Pigmentosa. Ophthalmol Sci. 2024 Jul 31;5(1):100589. doi: 10.1016/j.xops.2024.100589. eCollection 2025 Jan-Feb. PubMed 39328826 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — TRUST will follow specific plans for sharing of research data under the guidance of NIH's 2003 Data Sharing Policy. After analysis, the final data set can be provided after appropriate procedures are implemented to preserve the anonymity of the records, specifically where protected health information (PHI) is required. Upon request, anonymized data will be shared under confidentiality agreements with researchers interested in the project.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Time Frame will be determined.

Access criteria: Confidentiality agreements will be required before anonymized data will be shared.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2019 to primary completion in Nov 2023, 48 months.

Results were first posted in Dec 2024, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 6, 2019
First posted
Jun 11, 2019
StartActual
Oct 22, 2019
Primary completionActual
Nov 7, 2023
CompletionActual
Nov 9, 2023
Results first posted
Dec 2, 2024
Last update
Dec 2, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 2, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03981549
Lead sponsor
The Emmes Company, LLC
Responsible party
Sponsor
First posted
Jun 11, 2019
Start date
Oct 22, 2019
Primary completion
Nov 7, 2023
Completion
Nov 9, 2023
Results posted
Dec 2, 2024
Last update
Dec 2, 2024

Study contacts

Susanna S Park, MD, PhD
principal investigator · University of California, Davis

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion